Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
RESEARCH TOOLSreports
KROS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.78 - $73.00
Previous CloseN/A
Volume109.28K
Average Volume (3M)1.79M
Market Cap
$446.80M
Enterprise Value$1.67B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Feb 27, 2025EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.21
Shares Outstanding40,507,410
10 Day Avg. Volume1,040,074
30 Day Avg. Volume1,790,961
Standard Deviation0.23
R-Squared0.08
Alpha-0.00735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)660.19
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap3.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.52K
Enterprise Value/Ebitda-8.49
Forecast
1Y Price Target
$38.38Price Target Upside247.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Keros Therapeutics News
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Biotech Conference
---
Bulls Say, Bears Say
Bulls Say
Potential For GrowthDue to Keros’ strong balance sheet following its deal with Takeda and elritercept’s favorable milestones and royalties, there are multiple opportunities for growth outside of PAH.
Takeda PartnershipThe recent global partnership with Takeda for the development and commercialization of the anemia drug elritercept is seen as a positive development.
UndervaluationThe stock is considered undervalued at current levels even without credit to the PAH news, reflecting primarily cash with little credit to the Takeda partnership.
Bears Say
Limited Near-term CatalystsThere are limited near-term catalysts from the partnered elritercept program despite its proven differentiation and lowered risks.
Program TerminationKROS announced that they are terminating the Phase 2 TROPOS trial of cibotercept in pulmonary arterial hypertension following the observation of new pericardial effusion adverse events.
Safety ConcernsSafety concerns with the second lead asset, cibotercept, following observation of pericardial effusion in their ongoing Phase 2 study, led to a significant pullback in the stock.
---
Ownership Overview
8.69% Insiders
24.39% Mutual Funds
39.52% Other Institutional Investors
16.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.78 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $446.80M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Nov 06, 2024. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$1.279 by -$0.131.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -1.36.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 40,507,410 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.41 in its last earnings report, missing expectations of -$1.279. Following the earnings report the stock price went up 1.084%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
---
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.38 (247.96% Upside)
$38.38 (247.96% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.84%
12-Months-Change
Fundamentals
Return on Equity
-43.82%
Trailing 12-Months
Asset Growth
77.56%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Month Forecast
Average Price Target
$38.38
▲(247.96% Upside)
Technical Analysis
Fate Therapeutics
―
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Blueprint Medicines
―
Argenx Se
―
Best Analysts Covering KROS
1 Year
1 Year Success Rate
10/22 ratings generated profit
1 Year Average Return
+2.86%
reiterated a buy rating last month
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +2.86% per trade.
---